Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2023 02:53 ET | Source: The Insight Partners

Sickle Cell Disease Treatment Market Worth $4.69 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...
April 25, 2022 08:00 ET | Source: Sickle Cell Consortium

Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age

ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
February 16, 2022 07:00 ET | Source: Medunik USA

Hydroxyurea-based treatment for sickle cell anemia previously available for pediatric patients now approved for use in adults

ROSEMONT, PA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Medunik USA is pleased to announce that Siklos® (hydroxyurea), previously indicated to reduce the frequency of painful crises and to reduce the need...
July 16, 2021 08:40 ET | Source: CMI

Sickle Cell Disease Market in North America to Surpass US$ 2,200.5 Million by 2028, Says Coherent Market Insights (CMI)

SEATTLE, July 16, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the North America sickle cell disease market is estimated to be valued at US$ 770.5 Million in 2021 and is expected...
July 07, 2021 05:00 ET | Source: Global Market Insights, Inc

Prenatal and New-born Genetic Testing Market revenue to cross USD 9.5 Bn by 2027: Global Market Insights Inc.

Selbyville, Delaware, July 07, 2021 (GLOBE NEWSWIRE) -- According to latest report “Prenatal and New-born Genetic Testing Market by Technology (Screening, Diagnostic), Disease (Downs Syndrome,...
July 12, 2012 09:15 ET | Source: Vista Partners

Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price

SAN FRANCISCO, CA--(Marketwire - Jul 12, 2012) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) (NYSE Amex: ANX) ("The Company,"...
March 26, 2009 12:54 ET | Source: HemaQuest Pharmaceuticals

HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders

BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that it has received two orphan medicinal product designations from the European Commission for its product...
December 09, 2008 12:01 ET | Source: HemaQuest Pharmaceuticals

HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug

SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic...